Home | Links | Contact Us | More About Intellectual Property | Bookmark
Search patents:
Home Gene Therapy Lentiviral-packaging-constructs

 Method of treating cardiovascular diseases
OF PREFERRED EMBODIMENTS As examples of the diseases which the method according to the invention ...


 Rapid production of autologous tumor vaccines
In accordance with the present invention an autologous vaccine to tumor cells is produced by ...


 Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
OF THE INVENTION In accordance with the invention novel therapeutic use is provided for certain ...


 Engineered protein kinases which can utilize modified nucleotide triphosphate substrates
OF THE INVENTION Inhibition of Engineered Kinases FIG. 9 shows a schematic representation of an ...


 Method for the production of bacterial toxins
The present invention is based upon the discovery that bacterial toxin expression inhibitors ...


 Lactone stable formulation of 10-hydroxy 7-ethyl camptothecin and methods for uses thereof
OF PREFERRED EMBODIMENTS In its preferred embodiments, this invention involves preparation and ...


 Modified protein kinase A-specific oligonucleotides and methods of their use
The present invention relates to modified oligonucleotides useful for studies of gene expression ...


 Peptides and nucleic acid sequences related to the Epstein Barr virus
OF THE INVENTION The term "peptide" as used herein refers to a molecular chain of amino acids with ...


 Methods of optimizing drug therapeutic efficacy for treatment of immune-mediated gastrointestinal disorders
The present invention provides a method of optimizing therapeutic efficacy of 6-mercaptopurine drug ...


 Production of peptides in plants as viral coat protein fusions
What is claimed is: 1. A virion particle comprising a coat protein of a Tobamovirus and a fusion ...


 Lentiviral packaging constructs

Details
Inventors: Kaleko, Michael; Luo, Tianci; Plavec, Ivan; Douglas, Janet Lynn;
Assignee: Novartis AG (Basel, CH)
Primary Examiner: Guzo; David
Assistant Examiner:
Attorney, Agent or Firm: Bell, Boyd & Lloyd LLC

The present invention provides novel lentiviral packaging constructs that are useful for the establishment of stable packaging cell lines and producer cell lines. In particular, the present invention provides novel packaging cell lines that are capable of constitutively expressing high levels of lentiviral proteins.

DETAILED DESCRIPTION OF THE INVENTION The practice of the present invention will employ, unless otherwise indicated, conventional techniques of cell biology, molecular biology, cell culture, virology, and the like which are in the skill of one in the art.
These techniques are fully disclosed in current literature and reference in made specifically to Sambrook, Fritsch and Maniatis eds.
, "Molecular Cloning, A Laboratory Manual", 2nd Ed.
, Cold Spring Harbor Laboratory Press (1989); Celis J.
E.
"Cell Biology, A Laboratory Handbook" Academic Press, Inc.
(1994) and Bahnson et al.
, J.
of Virol.
Methods, 54:131 143 (1995).
All publications and patent applications cited in this specification are indicative of the level of skill of those skilled in the art to which this invention pertains and are hereby incorporated by reference in their entirety.
The present invention is concerned with novel lentivirus-based packaging constructs that are useful for the establishment of stable packaging cell line and producer cell lines.
Surprisingly it is found that mutations in the active site of the respective lentiviral protease gene enable the construction of lentiviral packaging vectors which are useful to establish stable packaging cell lines for the production of lentiviral vectors.
The catalytic center of HIV protease includes a three amino acid motif, Asp-Thr-Gly (Konvalinka, J.
et al.
,.
J.
Virol.
69:7180 7186, 1995) These three amino acids are conserved among HIV and SIV isolates documented so far (Korber B, Theiler J, Wolinsky S Science 1998 Jun.
19 280: 5371 1868 71).
Konvalinka, J.
et al.
mutated the Thr residue (corresponding to amino acid number 26 from the start of Protease in HIV isolate HXB2) to a Ser.
They found that the mutated HIV protease has a significantly reduced toxicity while preserving the protease activity.
It has been surprisingly found that this information makes it possible for one to generate a stable cell line to express high levels of lentiviral Gag/Pol proteins.
Expression of these proteins is absolutely necessary in order to establish a stable packaging cell line for lentiviral vectors, in particular for HIV- or BIV-based lentiviral vectors



Related patents
  Method for measuring no synthase activity
OF THE INVENTION In the context of the present invention the following definitions apply: Incubation: the introduction and leaving of a biological object, such as an ...
  Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
In one aspect, the present invention pertains to the discovery herein that Wnt polypeptides ("Wnts"), such as Wnt-5a, play a role in hematopoiesis. In another aspect, ...
  Hydrogel compositions for controlled delivery of virus vectors and methods of use thereof
The invention relates to a composition for delivery of a virus vector to an animal cell. The composition comprises a hydrogel precursor mixture having the virus vector ...
  Particle delivery techniques
OF THE PREFERRED EMBODIMENTS The practice of the present invention will employ, unless otherwise indicated, conventional methods of molecular biology and recombinant DNA...
  Tissue anchor system
The invention claimed is: 1. An adjustable tissue anchor comprising: a. an anchor body having a first and second open end with an interior chamber running between said ...
  Ribozyme mediated inactivation of the androgen receptor
The present invention describes inactivation of AR gene expression by engineering hammerhead ribozymes to cleave specific sites in AR mRNA. The present in vitro studies ...
  Thyrotropin-releasing hormone analogues and their therapeutic applications
The present invention pertains to novel TRH analogues, compositions, and methods for the controlled administration of novel TRH analogues to mammals. The present ...
  Probiotics in primary prevention of atopic diseases
What is claimed is: 1. A method for prevention of atopic diseases selected from the group consisting of atopic eczema, allergic rhinitis and asthma in an infant at high ...
  Humanin-like peptide and use thereof
The invention claimed is: 1. A polypeptide comprising an amino acid sequence as shown in SEQ ID NO: 4, or an amide, ester or salt thereof. 2. The polypeptide according ...
  Use of N-acetyl-D-glucosamine in the manufacture of pharmaceutical useful for suppressing side-effect of radiotherapy and chemotherapy
The invention claimed is: 1. A method for treating a cancer patient who is undergoing or has undergone a radiation therapy or chemotherapy treatment, the method ...

0.004

Archive: All patents - Links

Copyright (c)2006 Eipa-patents.org - All rights reserved